Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Rinnerthaler G, Gampenrieder SP, Hackl H, Steiner M, Monzo-Fuentes C, Melchardt T, Magnes T, Huemer F, Westphal T, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Rinnerthaler G, et al. Among authors: hauser kronberger c. J Clin Med. 2020 Jun 1;9(6):1663. doi: 10.3390/jcm9061663. J Clin Med. 2020. PMID: 32492882 Free PMC article.
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
Gampenrieder SP, Rinnerthaler G, Hackl H, Pulverer W, Weinhaeusel A, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Risch A, Greil R. Gampenrieder SP, et al. Among authors: hauser kronberger c. Theranostics. 2018 Mar 11;8(8):2278-2288. doi: 10.7150/thno.23544. eCollection 2018. Theranostics. 2018. PMID: 29721079 Free PMC article.
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, Westphal T, Riedmann M, Meissnitzer T, Egger H, Klaassen Federspiel F, Reitsamer R, Hauser-Kronberger C, Stering K, Hergan K, Mlineritsch B, Greil R. Gampenrieder SP, et al. Among authors: hauser kronberger c. Breast Cancer Res. 2019 Jan 31;21(1):19. doi: 10.1186/s13058-018-1091-y. Breast Cancer Res. 2019. PMID: 30704493 Free PMC article.
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
Schlick K, Hohla F, Hamacher F, Hackl H, Hufnagl C, Markus S, Magnes T, Gampenrieder SP, Melchardt T, Stättner S, Hauser-Kronberger C, Greil R, Rinnerthaler G. Schlick K, et al. Among authors: hauser kronberger c. Future Sci OA. 2020 Nov 30;7(2):FSO644. doi: 10.2144/fsoa-2020-0128. Future Sci OA. 2020. PMID: 33437513 Free PMC article.
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Rinnerthaler G, Gampenrieder SP, Petzer A, Hubalek M, Petru E, Sandholzer M, Andel J, Balic M, Melchardt T, Hauser-Kronberger C, Schmitt CA, Ulmer H, Greil R. Rinnerthaler G, et al. Among authors: hauser kronberger c. Ther Adv Med Oncol. 2021 Oct 19;13:17588359211042301. doi: 10.1177/17588359211042301. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34691243 Free PMC article.
Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT).
Westphal T, Gampenrieder SP, Rinnerthaler G, Balic M, Posch F, Dandachi N, Hauser-Kronberger C, Reitsamer R, Sotlar K, Radl B, Suppan C, Stöger H, Greil R. Westphal T, et al. Among authors: hauser kronberger c. Breast Care (Basel). 2022 Feb;17(1):1-9. doi: 10.1159/000512467. Epub 2021 Mar 30. Breast Care (Basel). 2022. PMID: 35355702 Free PMC article.
102 results